Cargando…

Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting

PURPOSE: To assess the levels of quality of life (QoL) in major depressive disorder (MDD) patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) as monotherapy for up to 6 months in a naturalistic clinical setting mostly in the Middle East, East Asia, and Mexico....

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Jihyung, Novick, Diego, Montgomery, William, Moneta, Maria Victoria, Dueñas, Héctor, Peng, Xiaomei, Haro, Josep Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621215/ https://www.ncbi.nlm.nih.gov/pubmed/26527865 http://dx.doi.org/10.2147/PPA.S89870

Ejemplares similares

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick, Diego, et al.
Publicado: (2016)

Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East
por: Hong, Jihyung, et al.
Publicado: (2017)

Should Unexplained Painful Physical Symptoms be Considered within the Spectrum of Depressive Symptoms?
por: Hong, Jihyung, et al.
Publicado: (2015)

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
por: Novick, Diego, et al.
Publicado: (2015)

Patient characteristics associated with treatment initiation among paediatric patients with Attention-Deficit/Hyperactivity Disorder symptoms in a naturalistic setting in Central Europe and East Asia
por: Hong, Jihyung, et al.
Publicado: (2014)

Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study
por: Novick, Diego, et al.
Publicado: (2017)

Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors
por: Sheehan, David V., et al.
Publicado: (2016)

Antidepressant medication treatment patterns in Asian patients with major depressive disorder
por: Novick, Diego, et al.
Publicado: (2015)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018)

Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity?
por: Novick, Diego, et al.
Publicado: (2013)

Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the worldwide schizophrenia outpatients health outcomes (W-SOHO) study
por: Hong, Jihyung, et al.
Publicado: (2012)

Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice
por: Qin, Xuan, et al.
Publicado: (2022)

Sex differences in the course of schizophrenia across diverse regions of the world
por: Novick, Diego, et al.
Publicado: (2016)

Antinociceptive Effects of the Serotonin and Noradrenaline Reuptake Inhibitors Milnacipran and Duloxetine on Vincristine-Induced Neuropathic Pain Model in Mice
por: Katsuyama, Soh, et al.
Publicado: (2014)

Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients
por: Novick, Diego, et al.
Publicado: (2016)

Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia
por: Hong, Jihyung, et al.
Publicado: (2013)

The potential efficacy of serotonin noradrenaline reuptake inhibitor duloxetine in dropped head syndrome: A case report and review of the literature
por: Funao, Haruki, et al.
Publicado: (2020)

Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study
por: Novick, Diego, et al.
Publicado: (2015)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice
por: Qin, Xuan, et al.
Publicado: (2023)

Predictors of duloxetine adherence and persistence in patients with fibromyalgia
por: Cui, Zhanglin, et al.
Publicado: (2012)

Schizophrenia Outpatient Health Outcomes study: twelve-month findings
por: Novick, Diego, et al.
Publicado: (2012)

Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis
por: Wozniak, Greta, et al.
Publicado: (2011)

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†
por: Montgomery, Stuart A, et al.
Publicado: (2014)

Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors
por: Briley, Mike, et al.
Publicado: (2010)

Clinical pharmacology of serotonin selective reuptake inhibitors /
por: Preskorn, Sheldon
Publicado: (1996)

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
por: Welsch, Patrick, et al.
Publicado: (2018)

Selective serotonin reuptake inhibitors and Alzheimer’s disease
por: Mdawar, Bernadette, et al.
Publicado: (2019)

Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression
por: James, Gregory M., et al.
Publicado: (2017)

Prenatal exposure to serotonin reuptake inhibitors: a case report
por: Marsella, Maria, et al.
Publicado: (2010)

Duloxetine, a Balanced Serotonin-Norepinephrine Reuptake Inhibitor, Improves Painful Chemotherapy-Induced Peripheral Neuropathy by Inhibiting Activation of p38 MAPK and NF-κB
por: Meng, Jing, et al.
Publicado: (2019)

Delayed Presentation of Posterior Reversible Encephalopathy Syndrome in the Setting of Serotonin-Norepinephrine Reuptake Inhibitors
por: Bhutada, Abhishek S, et al.
Publicado: (2022)

Serotonin and Noradrenaline Reuptake Inhibitors Improve Micturition Control in Mice
por: Redaelli, Marco, et al.
Publicado: (2015)

RAVE DRUG (ECSTASY) AND SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTI-DEPRESSANTS
por: Singh, A.N., et al.
Publicado: (2000)

Rapid response to selective serotonin reuptake inhibitors in post-COVID depression
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Serotonin Syndrome From Duloxetine Monotherapy: A Case Report
por: Li, Liumin, et al.
Publicado: (2023)

Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI)
por: Takata, Junko, et al.
Publicado: (2019)

Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study
por: Brugnoli, Roberto, et al.
Publicado: (2012)

A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
por: Zhong, Zhuoyuan, et al.
Publicado: (2017)

Effect of Serotonin Reuptake Inhibitors on Pulmonary Hemodynamics in Humans
por: Pleym, Hilde, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0cmspts60s0h1it9rtte3ra0o3